Un-audited financial results for the quarter and half year ended 30th September, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Samrat Pharmachem reported a standalone loss of Rs 58.73 lakhs in Q2 FY26 versus a profit of Rs 266.11 lakhs in Q2 FY25, and a half-year loss of Rs 81.62 lakhs versus a profit of Rs 472.66 lakhs in H1 FY25. Revenue from operations grew modestly, up about 12.4% year-on-year in Q2 to Rs 7,887 lakhs and just 2.3% higher in H1 at Rs 15,452 lakhs. The sharp swing to losses was driven by a steep rise in raw material costs, which jumped from Rs 14,192 lakhs in H1 FY25 to Rs 15,585 lakhs in H1 FY26, squeezing margins. EPS turned negative at Rs (2.64) for H1 versus Rs 15.30 a year ago. Despite the loss, the auditor (Shah & Savla LLP) issued an unmodified review report, and the balance sheet remains clean with no long-term debt and cash rising sharply to Rs 1,001 lakhs from Rs 5 lakhs, aided by higher trade payables.
Negative for shareholders in the near term — the company has slipped into losses despite revenue growth, signalling significant cost pressure and margin compression in its pharmaceutical chemicals business. Watch for evidence of margin recovery and stabilisation of input costs in coming quarters.